Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
M.pharm (Pharmaceutics) modern pharmacy unit-5 Study of consolidation parameters; Diffusion parameters, Dissolution
parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2
and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard
deviation , Chi square test, students T-test , ANOVA test
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
M.pharm (Pharmaceutics) modern pharmacy unit-5 Study of consolidation parameters; Diffusion parameters, Dissolution
parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2
and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard
deviation , Chi square test, students T-test , ANOVA test
Investigation of Medicinal Product Dossier (IMPD) and Investigator Brochure (...Tanvi Mhashakhetri
Contents:
European Medicines Agency (EMA)
IMPD Introduction
Contents of IMPD
Objectives
Scope
Introduction of IB
General Consideration
Content of IB
European Medicines Agency (EMA)
It is a decentralized agency of the European union.
The Management Board is the European Medicines Agency’s integral governance Body.
The Agency is responsible for the scientific evaluation, supervision and safety monitoring of the medicines developed by pharmaceutical companies use in EU.
EMA protects public and animal health in 27 EU member states, as well as the countries of the European economic area , by ensuring that all medicines available on the EU market are safe, effective and of high quality.
History
European medical agency was found in 1995, has worked across the EU and globally to protect public and animal healty by assessing medicines to rigorous scientific standards and providing with independent, science-based informations on medicines.
EMA has 20 year track record of ensuring efficacy and safety of human and veterinary medicines across Europe, and promoting research and innovation in the developments of medicines.
In first two decades, the agency recommended the authorization of the total of 975 humans and 188 veterinary medicines.
It contains details rules and regulations /legislation of Pharmaceuticals, Cosmetics, Active Substance Masters File, Investigational Medicinal Product Dossier for European Union
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
Introduction to ANDA
Regulations applied to ANDA process
Format and content of ANDA
ANDA approval process
Exclusivity
Hatch-Waxman amendments & 180 days exclusivity
Introduction to IMPD
Contents of IMPD
Introduction to IB
Contents of IB
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
2. CONTENTS
Dossiers
Goals of Dossier
Investigational medicinal product dossier (IMPD)
Objectives of IMPD
Data related to IMPD
Types of IMPD
IMPD in case of placebo
IMPD for marketed products
Introduction to Investigational Brochure (IB)
Table of content of IB
3. DOSSIERS:
» Actual meaning of “Dossier” is – a collection or file
of documents on some subjects, especially a file
containing detailed information about that topic.
E.g. Patient history file.
» Dossier ( or Registration Dossier ) of
pharmaceutical product is a document that
contains all technical data ( Administrative, Quality,
Clinical and Non-clinical data) of a pharmaceutical
product to be approved /registered/marketed in a
country.
4. DOSSIERS:
» Quality
» Efficacy
» Safety properties suitable for the
intended use
» Additional administrative
documents
» Sample of finished product or
related substances.
» Reagents necessary to perform
analysis of finished product.
» It is more commonly called
as:
» New Drug Application
(NDA) in the USA
» Marketing Authorization
Application (MAA) In
EU
» Or simply Registration
Dossier.
It consists of data proving that the drug has :
5. GOALS OF DOSSIER
» whether the drug is safe and effective in its
proposed use when used as directed, and do
the benefits of the drug outweigh the risk?
» Is the drug’s proposed labeling (Package
insert) appropriate and what it contains?
» Are the methods used in manufacturing the
drug and the controls used to maintain the
drug’s quality adequate to preserve drug’s
identity, strength, quality and purity.
6. INVESTIGATIONAL MEDICINAL PRODUCT
DOSSIER (IMPD)
» The Investigational Medicinal Product Dossier (IMPD)
is one of several pieces of Investigational Medicinal
Product related data, required whenever the
performance of a clinical trial is intended in one or
more European Union Member States.
» The IMPD includes summaries of information related
to the quality, manufacture and control of the
investigational Medicinal Product, data from non-
clinical studies and from its clinical use.
7. IMPD
» IMPDs are submitted as a part of clinical trial
application dossier, as the basis for the
approval of clinical trials by competent
regulatory authorities within the European
union.
8. Objectives of IMPD
» Clinical trails often to be designed as
multicentre studies, potentially involving
different member states.
» Aim of these guidelines to defines harmonized
requirement of documentation to be submitted
throughout the European community.
9. TYPES OF IMPDs
» The EU has provided for two types of IMPDs, “Full
IMPD” and a “Simplified IMPD”, based on whether
the product has been described previously in a
CTA or any other marketing authorization
application or not.
» Full IMPD is required when little or no information
about an IMP has been previously submitted to
competent authorities. When it is not possible to
cross-refer to data submitted by another sponsor
or when there is no MA in the community.
10. FULL IMPD
» It is required if no prior submission of any information
about the chemical or biological product is made to the
competent authority and in cases when information
cannot be cross referred.
» It also includes the summaries of information regarding
quality, manufacture and control parameters of IMP
along with non-clinical and clinical data including animal
pharmacology and toxicology studies, previous reports of
clinical trial and human experience with the product,
overall risk and benefit assessment.
11. SIMPLIFIED IMPD
» A simplified IMPD may be submitted if
information has been assessed previously as
part of a marketing authorization In any
Member State or a clinical trial to that
competent authority or when it is possible to
cross-refer to data In some other documents.
12. SIMPLIFIED IMPD
» The applicant has the possibility to refer to other documentation which may
be submitted alone or with a simplified IMPD:
1. Possibility to refer to the Investigational brochure (IB) for the preclinical and
clinical parts of the IMPD.
2. The applicant may submit the current vision of the SmPC (summery of
product characteristics) or document equivalent to the SmPC as the IMPD if
an IMP has a marketing authorization in any Member State or in an ICH
country.
The IMPD may have been submitted by the same applicant or by another
applicant, in these cases applicant are allowed to cross-refer to the previous
submission.
If submission was made by another applicant, a letter from that applicant
should be submitted authorizing the national competent authority to cross
refer that data.
14. DATA RELATED TO IMPD
» The IMPD can be replaced by other
documentation which may be submitted alone or
with simplified IMPD.
» It should be prefaced with a detailed table of
content and a glossary of terms.
» The information in the IMPD should be concise. It
should not be unnecessarily voluminous.
» It is preferable to present data In tabular form
accompanied by brief narrative highlighting the
main salient points.
16. A. QUALITY DATA
» Includes summaries of chemical,
pharmaceutical and biological data on quality of
any Investigational medicinal Product (IMP).
» Only those IMPs can be sent for clinical trial
whose manufacture complies with principles of
Good Manufacturing Practice.(GMP)
17. NOTE : In Exceptional cases, where impurities are not justified or when
unexpected impurities are detected, the certificate of analysis for test
product should be attached.
To document this requirement the applicant should provide the
following:
If the IMP is manufactured in the EU and does not have a marketing
authorization in the EU:
A copy of the manufacturing authorization.
If the IMP is not manufactured in the EU and does not have a
marketing authorization in the EU:
Certification of the Qualified Person that the manufacturing site work
in compliance with the GMP at least equivalent to EU GMP.
certification of the GMP status of any active biological substance.
copy of the importer’s authorization.
18. CTD Headings for Investigational medicinal product
“QUALITY DATA”
Drug substance
General Information.
Nomenclature.
Structure .
General Properties.
Manufacture:
Manufacturers.
Description of mfg
process and process
control.
Control of critical step
and intermediates.
Process validation &/or
Evaluation.
Mfg process
development.
Characterization
Structure elucidation and
other characteristics
Impurities
Control of Drug
substance:
Specification
Analytical Procedure
Validation of Analytical
Procedure
Batch analysis
Justification of specification
Reference standard or
material
Container closure
system
Stability
Medicinal product:
Description & Composition
of the medicinal product
Pharmaceutical
Development:
Drug substance
Excipients
Medicinal Product
Formulation Development
Overages
Physicochemical and
Biological Properties
Components of the
Medicinal Product
19. CTD Headings for Investigational medicinal product
“QUALITY DATA”
Manufacturing Process
Development
Container and closure
system
Microbiological
attributes
Manufacture:
Manufacturers.
Batch formula
Description of mfg
process and process
control.
Control of critical step
and intermediates.
Process validation &/or
Evaluation.
Control of excipients
Specification
Analytical procedure
Validation of analyticall
procedure
Justification of specification
Excipients of human and
animal origin
Novel excipients
Control of Medicinal
product:
Specification
Analytical Procedure
Validation of Analytical
Procedure
Batch analysis
Characterization of
impurities
Justification of
specification
Reference standard or
material
Stability
Appendices:
Facilities and equipments
Adventitious agents safety
evaluation
Novel excipients
Solvents for reconstitution
and diluents
20. B. Non-clinical Pharmacology and Toxicology
data
It should provide summaries of non-clinical pharmacology and
toxicology data for any IMP to be used in the clinical trial or
justify why they have not.
It should also provide a reference list of studies conducted and
appropriate literature references.
The summaries of studies conducted should allow an
assessment of the adequacy of the study and whether the study
has been conducted according to an acceptable protocol.
Sponsors should provide the non-clinical information in the
IMPD under the headings provided ahead:
21. CTD Headings for Investigational Medicinal Product for
“Non-clinical pharmacology and Toxicology data”
Pharmacodynamics
Brief summary
Primary
pharmacodynamics
Secondary
pharmacodynamics
Safety pharmacology
P’codynamics
interactions
Discussion and
conclusion
Pharmacokinetics
Brief summary
Methods of analysis
Absorption
Distribution
Metabolism
Excretion
P’cokinetic drug
interactions
Other P’cokinetic studies
Discussion and
conclusion including
evaluation of
toxicokinetics.
Toxicology:
Brief summary
Single dose toxicity
Repeat dose toxicity
Genotoxicity
In vitro
In vivo
Carcinogenicity
Reproductive and
developmental toxicity
Local tolerance
Other toxicity studies
Discussion and
conclusion.
22. C. Previous Clinical Trial and Human Experience Data
It should provide summaries of all available data from previous
clinical trials and human experience with proposed IMP in this
section.
All studies have been conducted in accordance with the
principles of GCP.
This should be confirmed by sponsor in the statement of the
GCP status of all studies and where this is not the case, he
should provide an explanation or justification if available.
Applications should take account of the general guidance on
clinical trials in the development of a medicinal product.
23. CTD Headings for Investigational Medicinal Product for
“Previous Clinical Trials and Human Experience Data”
Clinical pharmacology
Brief summary
Mechanism of primary action
Secondary p’cological effects
P'codynamic interactions
Clinical pharmacokinetics:
Brief summary
Absorption
Distribution
Metabolism
Excretion
P’cokinetics of active metabolite
Plasma concentration-effect
relationship
Dose and time dependence
Special patient populations
Interactions
Human exposure:
Brief summary
Overview of safety and efficacy
Healthy subject studies
Patient studies
Previous human experience
Benefits and risk assessment
24. D. Overall Risk and Benefit Assessment
It should provide a brief summary that analyses the non-clinical and
clinical data in relation to the potential risk and benefits of the
proposed trial.
Should use the relevant pharmacology, toxicology and kinetic results
to indicate possible risks in human.
Should identify any studies that were terminated permanently and
discuss the reasons.
Should discuss safety margins in terms of relative systemic exposure
to the investigational medicinal product, preferably based on :
● AUC
● Cmax Data
Rather than in terms of applied dose.
25. IMPD In Case of Placebo
If the Investigational Medicinal Product is a placebo, the information
requirements can be reduced in line with the requirements set out in
Table below:
26. IMPD for Marketed Products
The sponsor may submit the current version of SmPC
( summary of product characteristics) as the IMPD, if the
IMP has a marketing authorization in any member state in the
EU and is being used in same form, for the same conditions
and with a dosing regimen covered by the SmPC.
If the applicant is the marketing authorization holder and he
has submitted an application to vary the SmPC, which has not
yet been authorized, the nature of variation and the reason for
it should be explained in the covering letter.
27. There are situations where the IMP to be used in the clinical
trial has a Marketing Authorization (MA) in the Member
States (MS) but the protocol allows that any brand of IMP
may be administered to the trial subjects. In those situations,
providing that the IMP is not modified, it is acceptable that
IMPs to be used are only used are only identified by the
active substance name as follows:
IMPD for Marketed Products
28. Sponsor may wish to conduct a trial with an active substance that
is available in the community in a number of medicines with
Marketing Authorities and different trade names
In some trials the sponsor may wish to allow investigator in the
same multicentre trial to administer different regimens of IMPs.
In other trials the sponsor may wish to study the effect of a
number of medical treatment on specific illness without
specifying the IMPs t be used except that they have a Market
Authorization In the Member state concerned.
IMPD for Marketed Products
29. INVESTIGATION BROCHURE
Definition:
“It is a compilation of the clinical and non-clinical data
on the investigational products that are relevant to the
study of products in human subjects“
30. To provide information to the investigator and others involved in trials
with the information to facilitate their understanding of the rational role
for, and their compliance with, many key features of protocol, such as
dose, dose frequency, dose interval, methods of administration and
safety monitoring procedures.
Provide insight to support the clinical management for carryout clinical
trial study.
The information should be presented in concise, simple, objective,
balanced, and non promotional form that enables a clinician, or a
potential investigator, to understand it and make his own unbiased risk-
benefit assessment of the appropriateness of the proposed trial.
The IB should be reviewed at least annually and revised as necessary
in compliance with a sponsor’s written procedures.
PURPOSE OF INVESTIGATION BROCHURE (IB)
31. » Generally sponsor is responsible for up-to-date IB is made available
to the investigators and investigators are responsible for providing up-
to-date IB to the responsible IRBs/ IECs
» In case of an investigator sponsored trial, the sponsor-investigator
should determine whether the brochure is available from the
commercial personal.
» If investigational product is provided by the sponsor-investigator, then
he should provide the necessary information to the trial personal.
» In case where preparation of the formal IB is impractical, the sponsor-
investigator should provide, as substitute, an expanded background
information section in the trial protocol that contains the minimum
current information described in this guideline.
PURPOSE OF INVESTIGATION BROCHURE (IB)
32. It should include:
Title page:
Sponsor name
The identity of each investigational product (i.e. research number, chemical or
approved generic name & trade name)
The release date, reference number, date of edition.
Confidential statement-
sponsor may wish to include a statement instructing the investigator/
recipients to treat the IB as confidential document for sole information and use
of investigator’s team and IRB/IEC
Table of contents
Summary – Not exceeding 2 pages, Highlighting the Physical, Chemical,
Pharmaceutical, Pharmacological, Toxicological, Pharmacokinetic, Metabolic
and Clinical information available as per IP.
CONTENT OF INVESTIGATION BROCHURE (IB)
33. Introduction
Chemical name
Active ingredients
Pharmacological class
Anticipated- therapeutic / diagnostic indications
Description of IP- storage and handling, structural similarity of any other
compound.
Non-clinical studies – it may include following information
Species tested
Number of sex in each group
Unit dose (mg/kg)
Dose interval
Route of administration
Duration of dosing
CONTENT OF INVESTIGATION BROCHURE (IB)
34. Effects in human
Pharmacokinetic and product metabolism in human
Safety and efficacy
Marketing experience
Summary of data and guidance for the investigator-
It contains non-clinical and clinical data of IP.
Thus IB provide the investigator a clear understanding of –
The possible risks
Adverse reactions
Observation and precautions needed for clinical trials.
CONTENT OF INVESTIGATION BROCHURE (IB)
35. APENDIX OF GENERAL CONSIDERATION OF IB
1. TITLE PAGE
2. SPONSOR’S NAME
3. Product:
4. Research number:
5. Names : chemical, generic (if approved)
6. Trade names (if legally permissible and desired by the sponsor)
7. INVESTIGATOR’S BROCHURE
8. Edition number:
9. Release Date:
10. Replaces Previous Edition Number:
11. Date:
36. MAIN CONTENTS OF THE INVESTIGATOR’S BROCHURE
Confidentiality statement (optional)
Signature page (optional)
1. Table of contents
2. Summary
3. Introduction
4. Physical, chemical and pharmaceutical properties
5. Non-clinical studies
Non-clinical pharmacology
Pharmacokinetics and product metabolism in animals
Toxicology
6. Effects in humans
Pharmacokinetics and product metabolism in animals
Safety and efficacy
Marketing experience
7. Summary of data and guidance for investigator.
37.
38. REFERANCES:
Guideline on the requirements for the chemical and
pharmaceutical quality documentation concerning investigational
medicinal products in clinical trials EMA/CHMP/QWP/545525/2017
http://www.imp-dossier.eu/imdp_guidance/
https://www.fda.gov/drugs/investigational-new-drug-ind-
application/ind-applications-clinical-investigations-regulatory-and-
administrative-components
http://www.niche.org.uk/asset/insider-insight/Insider-
Investigator-Brochure.pdf